Plasma chemerin levels in patients with multiple sclerosis. 2014

Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski

OBJECTIVE Chemerin, a novel adipokine produced by adipose tissue and liver, is associated with markers of metabolic syndrome, and additionally, acting as chemoattractant for cells of immune system it may regulate immune cell properties. METHODS In order to evaluate plasma chemerin concentration in multiple sclerosis (MS) individuals we investigated 39 MS patients (among them 23 subjects were lean and 16 were overweight or obese) and 42 controls with tension headaches (29 of them were lean and 13 were overweight or obese). All patients had a brain MRI scan with gadolinium contrast as well as an assessment of the presence of oligoclonal bands in cerebrospinal fluid (CSF) and estimation of the CSF IgG index. The neurologic status was evaluated with use of the Expanded Disability Status Scale. Chemerin levels in plasma were measured using ELISA kit. Lipid profile, glucose and insulin levels, CRP and selected cytokine concentrations were also determined. RESULTS Plasma chemerin concentrations in overweight/obese MS subjects were higher when comparing to lean MS individuals and the controls, both from lean and overweight/obese subgroups. Significant difference was found between the results of overweight/obese MS and lean controls. CONCLUSIONS An increase of chemerin levels in patients with multiple sclerosis is associated with overweight and obesity.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013851 Thinness A state of insufficient flesh on the body usually defined as having a body weight less than skeletal and physical standards, such as BODY MASS INDEX, and dependent on age, sex, and genetic background. Leanness,Underweight
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
August 2020, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
March 2001, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society,
Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
April 2018, Journal of the neurological sciences,
Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
September 2008, Annals of general psychiatry,
Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
March 2017, Biomolecular concepts,
Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
November 2014, Peptides,
Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
January 1982, Metabolic, pediatric, and systemic ophthalmology,
Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
December 2009, Journal of the neurological sciences,
Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
January 2005, Journal of neuroimmunology,
Joanna Tomalka-Kochanowska, and Boguslawa Baranowska, and Ewa Wolinska-Witort, and Dorota Uchman, and Anna Litwiniuk, and Lidia Martynska, and Małgorzata Kalisz, and Wojciech Bik, and Jan Kochanowski
January 1980, Metabolic and pediatric ophthalmology,
Copied contents to your clipboard!